Compare · AYTU vs COLL
AYTU vs COLL
Side-by-side comparison of Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical Inc. (COLL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYTU and COLL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- COLL is the larger of the two at $790.2M, about 40.0x AYTU ($19.8M).
- Over the past year, AYTU is down 10.9% and COLL is down 43.8% - AYTU leads by 32.9 points.
- AYTU has been more active in the news (11 items in the past 4 weeks vs 8 for COLL).
- COLL has more recent analyst coverage (23 ratings vs 3 for AYTU).
- Company
- Aytu BioPharma Inc.
- Collegium Pharmaceutical Inc.
- Price
- -
- -
- Market cap
- $19.8M
- $790.2M
- 1M return
- -10.95%
- +9.72%
- 1Y return
- -10.95%
- -43.82%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 11
- 8
- Recent ratings
- 3
- 23
Aytu BioPharma Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Latest AYTU
- Aytu BioScience downgraded by Lake Street with a new price target
- SEC Form 10-Q filed by Aytu BioPharma Inc.
- SEC Form 425 filed by Aytu BioPharma Inc.
- Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results
- Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
- Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
- Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026
- FDA Approval for ZOLPIMIST issued to AYTU
Latest COLL
- President and CEO Karnani Vikram covered exercise/tax liability with 11,737 shares, decreasing direct ownership by 6% to 186,127 units (SEC Form 4) (for withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.
- SEC Form SCHEDULE 13G filed by Collegium Pharmaceutical Inc.
- SEC Form 10-Q filed by Collegium Pharmaceutical Inc.
- Collegium Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.
- Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
- Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
- Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses